http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2024, Vol. 33 ›› Issue (1): 57-62.DOI: 10.5246/jcps.2024.01.006

• 【药事管理与临床药学专栏】 • 上一篇    下一篇

2003–2020年中国仿制药上市和新药市场独占期研究

周从亚1, 黄涛1, 顾佳慧1, 李黄倩玉2, 史录文1,2, 管晓东1,2,*()   

  1. 1. 北京大学药学院 药事管理与临床药学系, 北京 100191
    2. 北京大学 医药管理国际研究中心, 北京 100191
  • 收稿日期:2023-10-03 修回日期:2023-11-12 接受日期:2023-12-15 出版日期:2024-01-31 发布日期:2024-01-31
  • 通讯作者: 管晓东

Generic development and market exclusivity period in China: an analysis from 2003 to 2020

Congya Zhou1, Tao Huang1, Jiahui Gu1, Huangqianyu Li2, Luwen Shi1,2, Xiaodong Guan1,2,*()   

  1. 1 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
    2 International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
  • Received:2023-10-03 Revised:2023-11-12 Accepted:2023-12-15 Online:2024-01-31 Published:2024-01-31
  • Contact: Xiaodong Guan

摘要:

中国近期提出给予新药、孤儿药和儿科药物6年的数据保护期, 以鼓励相关药物的研发创新。本研究评估了2003至2020年在中国批准上市的356种新小分子药物的仿制药上市情况和市场独占期。所有新药中, 155个(43.5%)新药有仿制药上市, 市场独占期中位数为5.6(四分位数: 2.4–9.4)年。进口药物、口服缓释药物和神经系统药物比其它药物的仿制药上市比例更高(P < 0.001, P = 0.039, P < 0.001)。国产药品的市场独占期中位数比进口药品更长(8.4 vs 5.7年)。市场独占期中位数从抗肿瘤和免疫调节剂的3.6年到消化道和代谢药物的6.8年不等。如果获得6年的数据保护期, 新药的市场独占期中位数预计将增加一倍。较长的市场独占期可能降低患者药品可及性, 政府在制定相关政策时应考虑在鼓励创新和确保药品可及性间寻求平衡。

关键词: 仿制药, 市场独占期, 小分子药物, 新药研发

Abstract:

China recently proposed a 6-year regulatory exclusivity period to incentivize research and development in new drugs, orphan drugs, and pediatric drugs. Our study assessed the generic entry status and the duration of market exclusivity for 356 new small-molecule drugs approved in China from 2003 to 2020. Of these, 155 drugs (43.5%) experienced generic entry, with a median market exclusivity period of 5.6 years (interquartile range: 2.4–9.4). Imported drugs, oral common-release agents, and drugs for the nervous system were more prone to generic entry (P < 0.001, P = 0.039, and P < 0.001, respectively). Domestic new drugs had a longer median market exclusivity (8.4 years) compared to imported drugs (5.7 years). Market exclusivity varied from 3.6 years for antineoplastic and immunomodulating agents to 6.8 years for drugs for the alimentary tract and metabolism. If the proposed 6-year regulatory exclusivity is implemented, the market exclusivity duration for new drugs is anticipated to double. It is essential for the government to carefully weigh the impact of such policies on balancing innovation incentives and ensuring drug affordability.

Key words: Generic drug, Market exclusivity period, Small molecule drugs, New drug development

Supporting: /attached/file/20240304/20240304210429_837.pdf